BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 31883967)

  • 21. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
    Dottermusch M; Schüller U; Hagel C; Saeger W
    Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
    Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
    Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
    Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.
    Lin S; Dai Y; Han C; Han T; Zhao L; Wu R; Liu J; Zhang B; Huang N; Liu Y; Lai S; Shi J; Wang Y; Lou M; Xie J; Cheng Y; Tang H; Yao H; Fang H; Zhang Y; Wu X; Shen L; Ye Y; Xue L; Wu ZB
    Genome Med; 2024 Apr; 16(1):60. PubMed ID: 38658971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
    Kurosaki M
    No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
    Kara M; Tokat F; Pamir MN; Danyeli AE
    Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
    Cui Y; Li C; Jiang Z; Zhang S; Li Q; Liu X; Zhou Y; Li R; Wei L; Li L; Zhang Q; Wen L; Tang F; Zhou D
    Neuro Oncol; 2021 Nov; 23(11):1859-1871. PubMed ID: 33908609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
    Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
    Uzilov AV; Taik P; Cheesman KC; Javanmard P; Ying K; Roehnelt A; Wang H; Fink MY; Lau CY; Moe AS; Villar J; Bederson JB; Stewart AF; Donovan MJ; Mahajan M; Sebra R; Post KD; Chen R; Geer EB
    J Clin Endocrinol Metab; 2021 Mar; 106(3):826-842. PubMed ID: 33221858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [WHO Histological Classification of Pituitary Tumors].
    Nishioka H
    No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?
    Asa SL; Mete O; Ezzat S
    Endocr Pathol; 2021 Mar; 32(1):3-16. PubMed ID: 33433883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
    Mete O; Asa SL
    Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
    Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
    Zhang Q; Yao B; Long X; Chen Z; He M; Wu Y; Qiao N; Ma Z; Ye Z; Zhang Y; Yao S; Wang Y; Cheng H; Chen H; Ye H; Wang Y; Li Y; Chen J; Zhang Z; Guo F; Zhao Y
    Cell Rep Med; 2023 Feb; 4(2):100934. PubMed ID: 36754052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggressive nonfunctioning pituitary neuroendocrine tumors.
    Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
    Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed Sparsely Granulated Lactotroph and Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor Expands the Spectrum of Neuroendocrine Neoplasms in Ovarian Teratomas: the Role of Pituitary Neuroendocrine Cell Lineage Biomarkers.
    Hodgson A; Pakbaz S; Shenouda C; Francis JA; Mete O
    Endocr Pathol; 2020 Sep; 31(3):315-319. PubMed ID: 32632841
    [No Abstract]   [Full Text] [Related]  

  • 37. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
    Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
    Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
    Asa SL
    Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
    Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
    Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
    Mete O; Kefeli M; Çalışkan S; Asa SL
    Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.